Advertisement
Screener

Aligos Therapeutics, Inc. (ALGS) Cash Flow Breakdown

Aligos Therapeutics, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Aligos Therapeutics, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $82.50M went out.
  • Fiscal year ended 2025-12-31: from investing, $37.83M went out.
  • Fiscal year ended 2025-12-31: from financing, $101.64M came in.
  • Fiscal year ended 2025-12-31: change in cash, $18.69M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew shares soldNot split outChange in cash
2025-12-31-$82.50M-$37.83M$304.00K$101.33M*-$18.69M
2024-12-31-$80.74M-$18.28M$436.00K-$98.67M
2023-12-31-$79.00M$44.98M$23.00K$88.31M*$54.31M
2022-12-31-$79.39M-$26.29M$205.00K-$105.52M
2021-12-31-$115.66M$3.02M$78.68M*-$33.96M
2020-12-31-$74.26M$32.76M$260.00K$192.09M*$150.84M
2019-12-31-$46.77M$6.79M$487.00K$85.05M*$45.56M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldNot split outChange in cash
2026-06-30-$24.95M*$25.00M*
2026-03-31-$23.13M$34.93M$11.74M
2025-12-31-$21.75M*-$2.02M*$124.00K*
2025-09-30-$24.34M*$47.68M*$0.00*
2025-06-30-$15.50M*-$39.42M*
2025-03-31-$20.91M-$44.07M$101.74M*$36.77M
2024-12-31-$18.40M*$19.97M*$139.00K*
2024-09-30-$20.10M*$10.40M*$0.00*
2024-06-30-$19.49M*$39.99M*
2024-03-31-$22.75M-$88.64M-$111.41M
2023-12-31-$22.66M*-$7.00K*$90.00K*$87.85M*
2023-09-30-$20.34M*-$9.00K*$0.00*
2023-06-30-$13.62M*$25.00M*$0.00*
2023-03-31-$22.39M$19.99M$23.00K-$2.40M
2022-12-31-$16.78M*$11.60M*$94.00K*
2022-09-30-$17.14M*$32.48M*$9.00K*
2022-06-30-$25.04M*-$9.98M*$1.00K*
2022-03-31-$20.43M-$60.40M$10.00K-$80.86M
2021-12-31-$37.48M*-$16.48M*$552.00K*
2021-09-30-$25.37M*-$40.00K*$18.00K*$77.93M*
2021-06-30-$23.02M*$9.85M*$213.00K*
2021-03-31-$29.80M$9.69M$96.00K-$20.02M
2020-12-31-$19.68M*$14.94M*$63.00K*$193.25M*
2020-09-30-$16.57M*$26.66M*$135.00K*-$1.08M*
2020-06-30-$17.69M*$14.93M*$44.00K*
2020-03-31-$20.32M-$23.77M$18.00K-$44.14M
2019-12-31-$15.02M*-$21.81M*$192.00K*$85.07M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Alector, Inc. (ALEC)United States$0.213B-1.90
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22